Home » Stocks » TXG

10X Genomics, Inc. (TXG)

Stock Price: $169.92 USD -1.83 (-1.07%)
Updated Jan 27, 2021 2:16 PM EST - Market open
Market Cap 18.48B
Revenue (ttm) 261.92M
Net Income (ttm) -134.29M
Shares Out 101.34M
EPS (ttm) -5.41
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 27
Last Price $169.92
Previous Close $171.75
Change ($) -1.83
Change (%) -1.07%
Day's Open 170.00
Day's Range 161.13 - 172.59
Day's Volume 420,928
52-Week Range 51.57 - 187.00

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Bloomberg Markets and Finance - 2 weeks ago

10X Genomics Strategy Driven By Innovation, CEO Says

Jan.12 -- 10X Genomics Inc. Chief Executive Officer Serge Saxonov discusses the company's strategy and performance amid the Covid-19 pandemic with Bloomberg's Vonnie Quinn on "Bloomberg Markets."

GlobeNewsWire - 1 month ago

PLEASANTON, Calif., Dec. 23, 2020 (GLOBE NEWSWIRE) -- 10x Genomics (Nasdaq: TXG) today announced the company will be participating in the upcoming 39th Annual J.P. Morgan Virtual Healthcare Co...

Seeking Alpha - 1 month ago

10X Genomics is a cutting edge, single-cell assay hardware, software and consumables company. Don't feel bad, I don't understand all of that either.

The Motley Fool - 1 month ago

Here's how these big businesses became enormous during a year most of us would rather forget.

Other stocks mentioned: MRNA, PFE, TDOC, VEEV
Seeking Alpha - 2 months ago

10X Genomics, Inc. (TXG) CEO Serge Saxonov on Q3 2020 Results - Earnings Call Transcript

Seeking Alpha - 2 months ago

10x Genomics, Inc. (TXG) CEO Serge Saxonov on Q3 2020 Results - Quick Version Earnings Call Transcript

Zacks Investment Research - 2 months ago

10x Genomics (TXG) delivered earnings and revenue surprises of 0.00% and 14.53%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 2 months ago

PLEASANTON, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- 10x Genomics, Inc. (Nasdaq: TXG) today reported financial results for the third quarter ended September 30, 2020.

GlobeNewsWire - 2 months ago

PLEASANTON, Calif., Nov. 04, 2020 (GLOBE NEWSWIRE) -- 10x Genomics (Nasdaq: TXG) today announced the company will be participating in the upcoming Stifel Virtual Healthcare Conference.

Zacks Investment Research - 2 months ago

10x Genomics (TXG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 3 months ago

PLEASANTON, Calif., Oct. 13, 2020 (GLOBE NEWSWIRE) -- 10x Genomics (Nasdaq: TXG) today announced it will report financial results for the third quarter 2020 after market close on Tuesday, Nove...

Seeking Alpha - 3 months ago

10x Genomics acquired ReadCoor, a Boston developer of In Situ technologies, for $350 million.

Other stocks mentioned: CRVS, INCY, ZLAB
Bloomberg Technology - 3 months ago

Covid-19 Vaccine Likely Early 2021, Says 10x Genomics CEO

Oct.07 -- Serge Saxonov, co-founder and chief executive officer at 10x Genomics Inc., discusses developments on a vaccine for Covid-19 on "Bloomberg Technology."

GlobeNewsWire - 3 months ago

Signs Agreement to Acquire ReadCoor; Acquires Sweden’s CartaNA AB Signs Agreement to Acquire ReadCoor; Acquires Sweden’s CartaNA AB

Seeking Alpha - 4 months ago

10x Genomics, Inc. has performed outstandingly well since the COVID-19 induced lows of March, more than doubling in this time.

GlobeNewsWire - 4 months ago

PLEASANTON, Calif., Sept. 15, 2020 (GLOBE NEWSWIRE) -- 10x Genomics, Inc. (NASDAQ: TXG) (the “Company”) today announced the closing of its public offering of 4,600,000 shares of its Class A ...

Zacks Investment Research - 4 months ago

3 Med Info Stocks to Improve Portfolio Health Amid Coronavirus Woes

Other stocks mentioned: MDRX, NXGN
GlobeNewsWire - 4 months ago

PLEASANTON, Calif., Sept. 10, 2020 (GLOBE NEWSWIRE) -- 10x Genomics, Inc. (NASDAQ: TXG) (the “Company”) today announced the pricing of an upsized underwritten public offering by the Company ...

GlobeNewsWire - 4 months ago

PLEASANTON, Calif., Sept. 08, 2020 (GLOBE NEWSWIRE) -- 10x Genomics, Inc. (NASDAQ: TXG) (the “Company”) today announced that the Company has commenced an underwritten public offering of 3,50...

The Motley Fool - 4 months ago

These shell companies allow the businesses they acquire to go public much more quickly than an IPO would. Is it time to buy in?

Other stocks mentioned: INVA, JAZZ, TBPH, TXAC
GlobeNewsWire - 4 months ago

PLEASANTON, Calif., Sept. 01, 2020 (GLOBE NEWSWIRE) -- 10x Genomics (Nasdaq: TXG) today announced the company will be participating in the upcoming Morgan Stanley Virtual Healthcare Conference.

Seeking Alpha - 5 months ago

10x Genomics went public in September 2019.

Seeking Alpha - 5 months ago

10x Genomics, Inc. (TXG) CEO Serge Saxonov on Q2 2020 Results - Earnings Call Transcript

GlobeNewsWire - 5 months ago

PLEASANTON, Calif., Aug. 11, 2020 (GLOBE NEWSWIRE) -- 10x Genomics, Inc. (Nasdaq: TXG) today reported financial results for the second quarter ended June 30, 2020.

GlobeNewsWire - 5 months ago

PLEASANTON, Calif., Aug. 06, 2020 (GLOBE NEWSWIRE) -- 10x Genomics (Nasdaq: TXG) today announced the company will be participating in the upcoming UBS Genomics 2.0 and Medtech Innovations Vi...

Seeking Alpha - 6 months ago

10x Genomics is growing fast and likely to become a successful life science tools company.

GlobeNewsWire - 6 months ago

Delivers major improvements for discoveries in immunology, oncology, autoimmunity, and infectious diseases Delivers major improvements for discoveries in immunology, oncology, autoimmunity, an...

GlobeNewsWire - 7 months ago

GSK, Johns Hopkins Medical Institutions, Mass General Cancer Center join global network to accelerate discoveries in COVID-19, oncology, immuno-oncology and neurology GSK, Johns Hopkins Medica...

Zacks Investment Research - 7 months ago

10x Genomics (TXG) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

GlobeNewsWire - 8 months ago

New solution accelerates research validation in cancer, immunology and drug discovery New solution accelerates research validation in cancer, immunology and drug discovery

GlobeNewsWire - 8 months ago

Pioneering Effort for Safe Workplace Reentry Pioneering Effort for Safe Workplace Reentry

Other stocks mentioned: ONEM
GlobeNewsWire - 8 months ago

Pioneering Effort for Safe Workplace Reentry Pioneering Effort for Safe Workplace Reentry

Other stocks mentioned: ONEM
Seeking Alpha - 8 months ago

10x Genomics, Inc. (TXG) CEO Serge Saxonov on Q1 2020 Results - Earnings Call Transcript

GlobeNewsWire - 9 months ago

Provides Preliminary Revenue Range for the First Quarter 2020

Bloomberg Technology - 9 months ago

Covid-19 Therapeutics Will Be Available Before a Vaccine, Says 10x Genomics CEO

10x Genomics Chief Executive Officer Sergei Samsonov and Bloomberg's Michelle Cortez discuss the race to find a cure for Covid-19. They speak with Bloomberg's Emily Chang on "Bloomberg Technol...

GlobeNewsWire - 9 months ago

Former Genomic Health CEO brings decades of healthcare experience to Board Former Genomic Health CEO brings decades of healthcare experience to Board

GlobeNewsWire - 11 months ago

Ships Chromium Connect; Unveils Dozen New Applications to Advance Genomics Ships Chromium Connect; Unveils Dozen New Applications to Advance Genomics

Seeking Alpha - 11 months ago

10x Genomics, Inc. (TXG) CEO Serge Saxonov on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 11 months ago

Despite the ongoing US-China trade war, increased focus on innovation is likely to have driven performance of medical products players' quarterly performance.

Other stocks mentioned: ABMD, BDX, CAH
The Motley Fool - 1 year ago

The company scored an important win in a patent dispute.

Forbes - 1 year ago

10x Genomics (NASDAQ: TXG), a biotechnology company that designs and manufactures gene sequencing technology, was listed following its IPO in September. While the stock saw some volatility pos...

GlobeNewsWire - 1 year ago

First Product Developed from Spatial Transcriptomics Acquisition First Product Developed from Spatial Transcriptomics Acquisition 

Seeking Alpha - 1 year ago

10x Genomics Inc. (TXG) CEO Serge Saxonov on Q3 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

10X Genomics: Little Droplets Of Information

The Motley Fool - 1 year ago

10X Genomics is growing revenue at a healthy clip, but a series of patent-infringement suits are hanging over the lab-hardware business.

GlobeNewsWire - 1 year ago

PLEASANTON, Calif., Sept. 16, 2019 (GLOBE NEWSWIRE) -- 10x Genomics (Nasdaq: TXG) today announced the closing of its initial public offering of 11,500,000 shares of its Class A common stock,...

Bloomberg Technology - 1 year ago

Single-Cell Analysis Breakthroughs Have Been Incredible, 10X Genomics CEO Says

10X Genomics Inc. Chief Executive Officer Serge Saxonov discusses the company's single-cell analysis technology with Bloomberg's Taylor Riggs on "Bloomberg Technology."

CNBC Television - 1 year ago

10x Genomics CEO Serge Saxonov on company's first trade

CEO of 10x Genomics Serge Saxonov discusses his thoughts on the company's growth and competition with "Squawk Alley".

24/7 Wall Street - 1 year ago

10X Genomics Inc. (NASDAQ: TXG) shares entered the market with a bang on Thursday.

CNBC Television - 1 year ago

SmileDirectClub, 10x Genomics set to IPO at the Nasdaq

CNBC's Leslie Picker takes a look at two IPOs, 10x Genomics and SmileDirectClub, set to debut at the Nasdaq today.

Other stocks mentioned: SDC

About TXG

10x Genomics, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. Its company offers chromium instruments, enzymes, microfluidic chips, slides, reagents, and other consumable products. The company's single cell solution runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the ... [Read more...]

Industry
Health Information Services
IPO Date
Sep 12, 2019
CEO
Serge Saxonov
Employees
584
Stock Exchange
NASDAQ
Ticker Symbol
TXG
Full Company Profile

Financial Performance

In 2019, 10X Genomics's revenue was $245.89 million, an increase of 68.06% compared to the previous year's $146.31 million. Losses were -$31.25 million, -72.22% less than in 2018.

Financial Statements

Analyst Forecasts

According to 8 analysts, the average rating for 10X Genomics stock is "Buy." The 12-month stock price forecast is 157.50, which is a decrease of -7.31% from the latest price.

Price Target
$157.50
(-7.31% downside)
Analyst Consensus: Buy